

Achievements and issues for Ph. Eur. Group of Experts on Veterinary Vaccines and Sera (15V)

Lukas Bruckner, Switzerland

Monographs Concerned

- *Clostridium novyi* (type B) vaccine for veterinary use (0362)
- *Clostridium perfringens* vaccine for veterinary use (0363)
- *Clostridium septicum* vaccine for veterinary use (0364)

- Cytotoxic Clostridia

Key Element of the Revision



Lukas Bruckner
Novel in-vitro model as alternative to in-vivo toxoid vaccines testing: Clostridium septicum vaccine as proof of concept, Virtual Workshop Webinar, EDQM, 9 & 10 March 2021

Tests Concerned

- Residual toxicity (*in process*)
- Antigen content (*in process*)
- Residual toxicity of the final product

- Batch potency test
- Identification

Lukas Bruckner
Novel in-vitro model as alternative to in-vivo toxoid vaccines testing: Clostridium septicum vaccine as proof of concept, Virtual Workshop Webinar, EDQM, 9 & 10 March 2021

Residual toxicity (*in process*)

Residual toxicity is assessed immediately after detoxification by a test in suitable cell cultures. The result complies with the value specified for the product.

- BSP 130 demonstrated that the move from the mouse test to the test in Vero cells is feasible for *C. septicum* toxoid
- It is assumed that residual toxicity of *C. perfringens* and *C. novyi* toxoids may be assessed in tissue cultures, as well
- According to EU guideline 2010/63 alternative methods must be applied, when available

Lukas Bruckner
Novel in-vitro model as alternative to in-vivo toxoid vaccines testing: Clostridium septicum vaccine as proof of concept, Virtual Workshop Webinar, EDQM, 9 & 10 March 2021

Antigen content (*in process*)

The antigen content is determined by a suitable *in vitro* method such as total combining power (TCP) using appropriate cell cultures as indicators of toxicity, an enzyme-linked immunosorbent assay (ELISA) or any other validated method

- New test, to monitor consistency of production
- TCP test considered as preferred test, because it is a functional test
- BSP 130 demonstrated that the TCP test using Vero cells is feasible for *C. septicum* toxoid
- It is assumed that the activity of *C. perfringens* and *C. novyi* toxoids can be assessed in a TCP test in tissue cultures, as well

Lukas Bruckner
Novel in-vitro model as alternative to in-vivo toxoid vaccines testing: Clostridium septicum vaccine as proof of concept, Virtual Workshop Webinar, EDQM, 9 & 10 March 2021

Residual toxicity of the final product

Test deleted

- Justification for this test is no longer given
 - Reversion to toxin probably due to false positive test results
- Sensitivity of the test questioned

Lukas Bruckner
Novel in-vitro model as alternative to in-vivo toxoid vaccines testing: Clostridium septicum vaccine as proof of concept, Virtual Workshop Webinar, EDQM, 9 & 10 March 2021

Batch potency test Identification

Minor editorial issues

- door openers to promote alternative *in vitro* test methods

Lukas Bruckner
Novel in-vitro model as alternative to in-vivo toxoid vaccines testing: Clostridium septicum vaccine as proof of concept, Virtual Workshop Webinar, EDQM, 9 & 10 March 2021

Thank you for your attention